FilingSEC EDGAR6-K
Radiopharm Theranostics Reports Clinical Pipeline Progress and Quarterly Cash Flow
· SEC accepted
StagePhase 1 and Phase 3 preparation
Filing content
The company announced progress across its clinical pipeline, including preparations for the RAD101 Phase 3 trial, and reported its cash flow and financing results for the quarter ended September 30.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…